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cancer; advance in gastric stem cell research and
the remaining challenges
Song-Ze Ding1,2* and Peng-Yuan Zheng3Abstract
Helicobacter pylori infection is the major cause of gastric cancer, which remains an important health care challenge.
Recent investigation in gastric stem cell or progenitor cell biology has uncovered valuable information in
understanding the gastric gland renewal and maintenance of homeostasis, they also provide clues for further
defining the mechanisms by which gastric cancer may originate and progress. Lgr5, Villin-promoter, TFF2-mRNA
and Mist have recently been identified as gastric stem/progenitor cell markers; their identification enriched our
understanding on the gastric stem cell pathobiology during chronic inflammation and metaplasia. In addition,
advance in gastric cancer stem cell markers such as CD44, CD90, CD133, Musashi-1 reveal novel information on
tumor cell behavior and disease progression implicated for therapeutics. However, two critical questions remain to
be of considerable challenges for future exploration; one is how H. pylori or chronic inflammation affects gastric
stem cell or their progenitors, which give rise to mucus-, acid-, pepsinogen-, and hormone-secreting cell lineages.
Another one is how bacterial infection or inflammation induces oncogenic transformation and propagates into
tumors. Focus on the interactions of H. pylori with gastric stem/progenitor cells and their microenvironment will be
instrumental to decipher the initiation and origin of gastric cancer. Future studies in these areas will be critical to
uncover molecular mechanisms of chronic inflammation-mediated oncogenic transformation and provide options
for cancer prevention and intervention. We review recent progress and discuss future research directions in these
important research fields.
Keywords: Helicobacter pylori (H. pylori), Cancer, Stem cell, Gastric epithelial cells, EpigeneticsIntroduction
Helicobacter pylori, a microaerophilic, spiral-shaped
Gram-negative bacterium, colonized in human stomach,
is the major cause of chronic gastritis, peptic ulcers, and
gastric malignancies, including gastric non-cardia adeno-
carcinoma and mucosal-associated lymphoid tissue
(MALT) lymphoma [1]. Epidemiologically, H. pylori
infects half of the world’s population, although most
infected persons have no clinical presentation, approxi-
mately 1% infected people will develop into gastric can-
cer [2]. Despite ample amount of efforts in investigating
its pathogenesis and host-pathogen interactions, the* Correspondence: dingsongze@hotmail.com
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distribution, and reproduction in any mediummolecular mechanisms of how H. pylori infection
induces gastric cancer remain poorly understood.
Gastric cancer (GC) is the second leading cause of
cancer related death among all cancers, next only to
lung cancer. Although the relationship between H. pylori
infection and gastric cancer has been very well estab-
lished, the mechanisms of how tumor initiation and the
early development remain elusive. Studies in past dec-
ades have suggested that stem cells play a pivotal role in
the initiation of gastric cancers, and the tumor can ori-
ginate from bone marrow derived cells [3]. However, it
is not clear how they give rise to tumors after inflamma-
tory insult or bacterial infection; in this work, we briefly
discuss the current progress and important challenges
for future research.tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Major H. pylori virulence factors and their functions
Name Size/genes Effects in host cell Reference
CagA 120-140 kDa Oncoprotein, disrupt cell polarity, multiple cell signaling [6]
cagPAI about 30 genes Type VI secretion system for CagA, PGN injection, and NF-κB activation [4,5]
VacA 88 kDa protein Vacuolization, apoptosis and inhibiting cell proliferation [7]
OMPs 33 members Inflammation and adhesion [8]
CagA cytotoxin-associated antigen A; cagPAI cag-pathogenicity island; VacA vacuolating cytotoxin; PGN peptidoglycan; OMPs outer membrane proteins.
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gastric epithelial cells
Four major virulence factors have been identified from
H. pylori (Table 1), including cytotoxin-associated antigen A
(CagA), cag-pathogenicity island (cagPAI), vacuolating
cytotoxin (VacA), and outer membrane proteins (OMPs).
H. pylori cagPAI is a 40 kilobase region of H. pylori genome
that encodes about 30 genes, some of them encode type four
secretion system (TFSS), which are essential for pathogen-
esis and are responsible for delivery of CagA protein and
peptidoglycan (PGN) into host cells [4,5]. H. pylori CagA is
encoded by cagA gene within the cagPAI, has a molecular
weight around 120–145 kDa, induces multiple host cell sin-
galing [6]. VacA is an 88-kDa bacterial protein and toxin,
which can undergo limited proteolytic cleavage to yield two
p33 and p55 subunits. Major effects of VacA include causing
host cell vacuolization, apoptosis and inhibiting cell prolif-
eration [7]. OMPs including Hop (Helicobacter outer mem-
brane porins) and Hor (Hop-related proteins) groups
proteins that include 33 members, their functions are asso-
ciated with enhanced gastric mucosa inflammation and are
necessary for bacteria adhesion to epithelial cells [8]. Infec-
tion with cagPAI- and cagA-positive H. pylori strains is
linked to increased gastric cancer risk [1,2].
H. pylori CagA and PGN are injected into host cell cyto-
plasm following its adherence to gastric epithelial cells,
and induce CagA- and cagPAI-dependent effects on epi-
thelial cells [4,5]. The basis for pathogenesis and clinical
presentation is that H. pylori virulence factors activate
multiple intracellular pathways in epithelial cells, such as
mitogen-activated protein kinases (MAPK), NF-κB, activa-
tor protein (AP)-1, Wnt/β-catenin, signal transducer and
activator of transcription 3 (STAT3) and phosphatidylino-
sitol 3-kinase (PI3K). Their expression lead to increased
inflammatory cytokine production, immune cell infiltra-
tion, affecting host cell apoptosis, proliferation and differ-
entiation, finally result in clinical presentation and
epithelial cell oncogenic transformation [2,9].
CagA specific effects include activation of Src-homology
2 domain-containing tyrosine phosphatase (SHP-2), up-
stream of Ras/Raf/Mek/Erk cascade; disruption of epithe-
lial cell barrier function through dephosphorylation of
cortactin, ezrin, associate with ZO-1; and binding to Par1/
MarkII complex that damage normal cell contact, cell po-
larity, and epithelial cell permeability [6]. CagA alsoactivates nuclear factor of activated T-cells (NFAT) signal
pathway, and interacts with E-cadherin to deregulate
β-catenin signaling, which induces β-catenin downstream
genes expression such as CDX1 and promotes cell intes-
tinal transdifferentiation [10].
Major cagPAI-dependent host signaling involve introdu-
cing PGN into host cell cytoplasm and activate NF-κB by
Nod 1 signaling [4,5]. Activation of NF-κB mediates the
expression of multiple genes involved in H. pylori-induced
host responses, such as expression of interleukin (IL)-6,
-8. In addition, recent studies indicate H. pylori infection
also causing epigenetic changes in gastric epithelial cells
including DNA methylation and histone modifications [9].
Further investigation in these areas will lead to the discov-
ery of important molecular mechanisms in bacteria-
induced gastric cancer.
Bacterial and host factors involved in gastric
cancer related to H. pylori infection
Infection with H. pylori in mice and gerbils, and infection of
H. felis in mice results in stomach inflammation and eventu-
ally leads to the step-wise histopathologic changes presented
as chronic atrophic gastritis, intestinal metaplasia, dysplasia,
and gastric adenocarcinoma [11-13]. The results implicate
synergistic interactions among Helicobacter components,
inflammation and host factors for gastric carcinogenesis.
Recent studies have begun to address individual bacterial
and host components in pathogenesis.
H. pylori CagA
H. pylori CagA is a bacterial oncoprotein and is suffi-
cient to generate gastric cancer alone in mice. Trans-
genic mice that overexpress bacterial CagA protein
alone induce multiple malignancies [14], including gas-
tric epithelial hyperplasia, hyperplastic polyps, gastro-
intestinal carcinomas, and hematological malignancies.
The mice have no signs of gastritis or systemic inflam-
mation, and the cancers are cell autonomous. These
results directly indicate the role of CagA in gastric
tumorigenesis, although the detailed mechanisms remain
to be explored further.
Wnt/β-catenin and cyclooxygenase 2 pathways
H. pylori infection activates Wnt/β-catenin and cycloox-
ygenase 2 (COX2)/prostaglandin E(2) pathways that play
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known that H. pylori infection induces β-catenin and
p120 expression which mediate peroxisome proliferator-
activated receptor δ expression in gastric epithelial cells,
and promotes gastric epithelial cell proliferation, these
effects have been attributed to the cag secretion system
substrates CagA and peptidoglycan [15]. Activation of
β-catenin pathway also leads to targeted transcriptional
up-regulation of genes that implicated in carcinogenesis,
such as NFAT signaling [10,11].
Transgenic mice that overexpress COX2 and Wnt1
each alone do not produce tumor, but cross the two
components to generate K19-Wnt1/C2mE mice, which
express both COX2 and Wnt1, induce cancer in these
mice. In the stomach of these mice, macrophages are
also recruited to the gastric mucosa, and promote tumor
formation [13,16], suggesting combined actions or syner-
gistic effects of COX2 and Wnt signaling pathways on
the cancer formation processes.
Inflammatory cytokines
Infection of H. pylori also disrupts gastric homeostasis
and induces multiple inflammatory cytokine production
within local mucosal, components such as IL-1β, TNF-α,
and IL-10 genotypes are associated with increased risk
for developing gastric cancer [17-19].
IL-1β is a proinflammatory cytokine involved in in-
flammation and immunity. IL-1β polymorphisms are
associated with enhanced IL-1β production and
increased risk of gastric cancer [19], IL-1β also inhibits
gastric acid secretion. In transgenic mice, stomach spe-
cific overexpression IL-1β induces stepwise spontaneous
gastric inflammation, metaplasia, dysplasia, and carcin-
oma. H. felis infection results in more rapid progression
to gastric atrophy and cancer. Overexpression of IL-1β
also mobilizes myeloid-derived suppressor cells and
induces NF-κB activation as well as its downstream
genes IL-6, TNF-α expression in these cells. In addition,
IL-1β alone is sufficient to induce gastric preneoplasia
[17]; however, it is not clear the mechanisms of how IL-
1β over expression itself finally results in oncogenic
transformation at present.
Interestingly, other inflammatory mediators can exert
opposite effects. One example is IFN-γ, which is pro-
duced primarily by activated T cells, natural killer cells
and is a key mediator of innate and adaptive immunity.
IFN-γ mediates responses to bacterial infection and
autoimmune disease, and acts as tumor suppressor [18].
In mice, stomach specific overexpression of IFN-γ alone
has minimal effects on gastric mucosa, but inhibits IL-
1β- and H. felis–induced gastritis and neoplasia. The
mechanism has been attributed to IFN-γ inhibits gastric
epithelial cell proliferation, accelerates apoptosis of gas-
tric T lymphocytes and decreases production ofproinflammatory Th1 and Th17 cytokines. These effects
may balance epithelial cell proliferation, restrain inflam-
mation, and ultimately inhibit tumor formation [18].
Therefore, disruption of host cell inflammatory cytokine
production participates in gastric oncogenesis.
Trefoil factors
The trefoil factor family proteins (TFF1, 2, 3), regulate
mucosal repair and suppress tumor formation in stom-
ach. TFF1 and TFF2 have recently been identified to play
a critical role in antagonizing gastric carcinogenesis
[20,21]. Tff1 acts as a tumor suppressor gene and its de-
ficiency results in spontaneous gastric cancer in mice
[21]. Tff2 deficient mice only display subtle alterations in
mucosal proliferation; parietal cell activation presented
as increased acid secretion and increased susceptibility
to NSAID injury. Genetic ablation of Tff2 accelerates
tumor growth and promotes preneoplastic lesions in mice
antrum [20]. In these mice, imbalance of hormone and
cytokine production was noted, with decreased gastrokine
1, 2 mRNA production and increased Th1 response,
decreased Th2 response (IL-1α, β and interferon-γ, reduced
IL-13, IL-4) [20,21].
Both TFF1 and TFF2 expression are frequently lost in
gastric cancer and aberrant promoter methylation has
been suggested to be an important mechanism. Interest-
ingly, H. felis infection enhances the loss of TFF1, and
H. pylori (SS1 strain) infection increases Tff2 promoter
methylation in mice which results in the lower level of
protein expression [20,21]. Therefore, these data reveal
protective effects of TFF proteins and their reduction
promote gastric carcinogenesis.
Together, the above systems have clearly advanced our
understanding of the role of H. pylori or host factors in
gastric carcinogenesis; although the data are fairly frag-
mentary, they can be converged and potentially impact
on gastric stem or progenitor cells toward carcinogen-
esis. In fact, the role of stem or progenitor cells in these
model systems has just begun to be appreciated. Studies
have now moved to address the tumor initiation and
malignant transformation by focusing on stem cell,
microenvironment, and recruitment of various progeni-
tor cells that contribute to tumor growth, which will be
discussed in more detail below.Gastric stem or progenitor cells and their markers
Gastric epithelial cells that make up the gastric gland in
mucosa are pit, parietal, neck, and zymogenic cells, as
well as the progenitor cells. Two important limitations
in stem cell research are lack of in vitro culture system
and shortage of specific markers for different stages of
stem cells. Recent studies begin to identify these cells by
mouse genetics lineage tracing analysis, which is a
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cell markers and their functions.
The original concept of gastric cancer stem cell hy-
pothesis is that cells located in the isthmus region of
gastric gland, the morphologically immature cell with
less organoid, are multipotent stem cells; they are re-
sponsible for generating the four major cell types of gas-
tric gland [22]. These stem cells give rise to transit
amplifying (daughter/progenitor) cells, which can differ-
entiate into all mature cell types. During this process,
descendants derived from stem cells undergo a complex
bipolar migration from neck/isthmus region, moving ei-
ther upward or downward. In mouse stomach, all three
types of progenitor cells (prepit, preneck, and preparietal
cells) have been found to originate from multipotent
granule-free cells in isthmus region [22]. However, this
model has recently been enriched with the discovery of
proliferating Villin-promoter- and Lgr5-marked cells
(see below) at the base and various locations of pyloric
glands, which exhibit both self-renewal and the ability to
generate all differentiated epithelial cell types of the pyl-
oric gland [23,24]. These observations have opened new
avenues to investigate gastric stem cell biology and
pathobiology.
Genetic linage tracing marked gastric stem cells
Several recently identified gastric stem or progenitor cell
markers using genetic linage tracing technology are
listed in Table 2.
Lgr5 marked gastric stem cells
Using in vivo linage tracing analysis, Barker and collea-
gues [23] demonstrate that Lgr5 (leucine-rich repeat-
containing G protein-coupled receptor 5, Gpr49)
marked cells are long live; reside in the gland base,
morphologically immature, with a large nuclear-
to-cytoplasmic ratio and limited organelles. Lgr5 is a
Wnt target gene identified in colon cancer cell lines, and
intestinal crypts. It is recently identified as a novel stem
cell marker of stomach, intestinal epithelium and hair
follicle [23].
In neonatal mice stomach [23], Lgr5 is expressed at
the base of corpus and pyloric glands, whereas in adult
mice Lgr5 is predominantly restricted to the base ofTable 2 Gastric stem and progenitor cell markers
Name Location Fu
Lgr5 Antral, gland base Gi
Villin-promoter Antral, gland base Gi
Tff2 mRNA Corpus, gland base Gi
Mist1 (BHLHA15) Corpus, gland base Ch
Lgr5 leucine-rich repeat-containing G protein-coupled receptor5 (Lgr5); Villin-promo
stem cells; Mist1 (BHLHA15), basic helix-loop-helix family, member a15.mature pyloric glands. In contrast to the common con-
cept that stem cell are quiescent, Lgr5 marked cells, pro-
liferate fast and are able to build up the entire gastric
gland over a short time. During in vitro culture, single
Lgr5 positive cell efficiently generated long-lived orga-
noids resembling mature pyloric epithelium with self-
renewing capability, architecture and cell composition.
Study the transcriptome of Lgr5 cells [23] reveal total
of 153 changed genes expression in Lgr5 stem cell/
daughter cell population, many are Wnt target genes, in-
cluding CD44, Sox9, Sord, Prss23, Sp5, indicating canon-
ical Wnt signaling activity at the base of pyloric glands.
Several enteroendocrine-specific genes, including Chro-
mogranin A&B, Somatostatin, and Gastrin G, are highly
upregulated in Lgr5 daughter cell population, implying
rapid differentiation toward the enteroendocrine lineage.
Lgr5 stem cells are also tumorigenic, mice with dele-
tion of APC gene, an essential Wnt signaling gene
resulted β-catenin upregulation at the base of pyloric
glands, and within 2–3 weeks, these Lgr5 cells can grow
into highly proliferative, β-catenin-positive adenomas.
This effect is not detected in gastric corpus, confirming
the absence of Lgr5 in this region [23].
Because of these exciting discoveries, distribution of
Lgr5 cells is further examined in human stomach.
Immunostaining revealed relocation of Lgr5 cells in dif-
ferent stages of gastric diseases [25]. In non-neoplastic
stomach mucosa, Lgr5 cells are found predominantly in
mucous neck region; during intestinal metaplasia, they
localize at the crypt base; and in GC, Lgr5 cells are
present at the luminal surface, tumour center and the in-
vasion front. Distribution of Lgr5 cells in tumor center
and invasion front of GC correlates well with tumor
growth and nodal spread. In addition, patients with Lgr5
positive GCs have a shorter median survival than
patients with Lgr5 negative GCs. Tumor tissues from
esophagus, stomach, liver, pancreas, colon and rectum
all show significantly more Lgr5 cells and higher levels
of Lgr5-mRNA expression when compared with non-
tumor tissues [25].
Together these observations in mice and human have
documented that stem cells are far more mobile and less
restricted to the positions as they were originally
thoughts. In addition, Lgr5 marked cancer cells cannction Reference
ve rise to gastric unit, all four types of cells [23]
ve rise to gastric unit, all four types of cells [24]
ve rise to only parietal, neck, and chief cells [27]
ief cell for SPEM generation [28]
ter Villin-promoter marked stem cells; Tff2 mRNA, Trifold factor 2 mRNA marked
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indicating an invasive growth property and imply that
they are crucial for gastric cancer development and pro-
gression. Further studies are required to understand
their roles in gastric tumorigenesis especially during the
chronic H. pylori infection setting. Interestingly, the
trend has already begun; pilot report has shown that
H. pylori infection is associated with increased DNA dam-
age of Lgr5 positive cells in gastric cancer patients [26].
Villin-promoter marked gastric stem cells
Villin is an actin-binding-protein, mainly expressed in
the brush border of intestinal epithelium, plays a key
role in the morphogenesis of microvilli to form mem-
brane protrusions that increase cell surface area and in-
volve in cell absorption, secretion and adhesion. Villin is
highly expressed in intestinal cell and largely devoid
from gastric epithelial cell.
Lineage tracing studies confirm that Villin-promoter
marked cells can be found in mice gastric epithelium,
they are quiescent and locate at, or below isthmus in the
bottom third part of pyloric glands and rare in corpus
[24]. These cells give rise to multiple gastric lineages of
antral glands, including surface pit cell (mucous gland
cells), enteroendocrine cells, and parietal cells. However,
endogenous Villin protein expression is not observed in
the gastric epithelia of these mice probably due to gene
structural disruptions; therefore it is difficult to establish
the precise relationship of active and quiescent stem cell
populations. Similar to Lgr5, Villin-promoter marked
stem cell population are also absent in the corpus region
and indicate different stem cell biology in this region of
stomach [24].
One important finding from this elegant work is that
forced IFN-γ exposure in mice to mimic inflammation
cause remarkable expansion of Villin-promoter marked
cell population in antral mucosa [24]. The marked cells
can be found to locate at various positions in the lower
portion of the gland, between isthmus and gland tip, and
situated on the opposite side of gland base, suggesting
inflammation regulates these cell proliferation and mi-
gration. While using CDX2 transgenic mice, a model to
induce intestinal metaplasia, find no significant change
in both cell number and locations, implicating Villin-
promoter marked cells do not give rise to the metaplasia.
It would be interesting to see if other inflammatory
mediators might impact on these cells and alter their
amplification and mobility as well.
Trefoil factor 2 mRNA marked gastric stem/progenitor cells
In gastric gland, mucus neck cells locate below the isth-
mus region and express trefoil factor family 2 proteins;
but TFF2 mRNA transcripts are concentrated in cells
above the neck region in normal corpus mucosa. Thispositional change suggests that TFF2 mRNA transcript-
expressing cells (TTE) might be gastric progenitor cells
and TFF2 mRNA transcripts may be a marker [27].
In oxyntic mucosa [27], lineage tracing demonstrate
that TFF2 mRNA marked cells migrate toward the bot-
tom of the gland, give rise to parietal, mucous neck, and
chief (zymogenic) cell lineages, but not enterochromaf-
fin-like-cell. Surface mucus cells are not derived from
TTE cells and the progeny of the TTE lineage do not
survive beyond 200 days [27]. In contrast to corpus, in
antrum, TTE cells do not appear to migrate, nor are they
represent any type of stem or progenitor cell in distal
stomach, suggesting TTE marked cells only located in
the gastric corpus. However, functional data are not
available from this study, future studies are required to
understand its role in gastric gland renewal and differen-
tiation during inflammation.Mist1 marked gastric stem/progenitor cells
Mist1 (BHLHA15) is a transcription factor, expressed in
chief cells and is critical for chief cell basal localization
and maintenance. It is expressed at the base of gastric
gland and in cells located at transition zones between
the neck and base region with partial neck-chief cell
characteristics [28].
Lineage tracing in acute and chronic oxyntic atrophy
mice models with Mist1 expressing cells (using chemical
L-635 treatment and H. felis infection) demonstrate that
chief cell can give rise to entire spasmolytic polypeptide-
expressing metaplasia (SPEM) lineage. SPEM is a re-
cently appreciated form of gastric mucosal metaplasia in
addition to intestinal metaplasia, SPEM get it name due
to it expresses TFF2 (spasmolytic polypeptide), also
called pseudopyloric metaplasia or mucous metaplasia
or antralization of the corpus [29]. Chief cells may there-
fore represent progenitor cells for metaplasia [28]. Loss
of parietal cells induces transdifferentiation of chief cell
into SPEM and this metaplasia can undergo expansion
under the influence of acute or chronic inflammation.
Gastric atrophy of corpus and body are associated with
the development of SPEM, and SPEM is strongly asso-
ciated with the development of gastric cancer similar to
intestinal metaplasia. Both SPEM and intestinal metapla-
sia are observed in the stomachs of gastric cancer
patients. SPEM possesses the characteristics of antral
metaplasia and express TFF2 and MUC6, while intestinal
metaplasia demonstrates clear lineage characteristics of
duodenum of intestines, with expression of TFF3 and
MUC2 [28,29]. At present, it is not clear if gastric cancer
might arise from either one or none of both types
of metaplasia, future work are warranted to evaluate
their relationship and the role of SPEM in gastric
carcinogenesis.
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For brief summary, a few recently reported putative gas-
tric stem cell and cancer stem cell markers are listed in
Table 3.
Cluster of differentiation 44 (CD44)
CD44 is a cell surface transmembrane glycoprotein that
acts as a receptor for extracellular matrices such as
hyaluronic acid, its function involves in cell–cell inter-
action, cell adhesion and migration. CD44 is a known
downstream target of Wnt/β-catenin pathway and is
expressed in many types of tissues, and solid tumors
such as gastric, pancreas, colon cancers [30-33]. CD44
has a variety of splicing variants (CD44v) [30] and is
identified as a solid tumor stem cell marker in breast
cancer [31]. CD44 expressing cells have cancer stem cell
(CSC) features including; tumorigenic, able to self-
renewal and generate phenotypically diverse (mixed
populations of ) nontumorigenic cells.
In SCID (severe combined immunodeficiency) mice,
CD44 positive gastric cancer cells are able to induce
tumor [32], knockdown CD44 by short hairpin RNA
decreases the tumorigenicity. Furthermore, these cells
are resistant to chemotherapy or radiotherapy. In the
same experiment, other potential CSC markers, such as
CD24, CD133, CD166, stage-specific embryonic antigen-
1 (SSEA-1), and SSEA-4, or sorting for side population
of cells do not show any correlation with tumorigenicity
in vitro or in vivo [32]. In addition, recent reports indi-
cate CD44, ADAM17 and another putative stem cell
marker, Musashi-1 coexpresses with stem cell markers
Lgr5 in both normal and gastric cancer patient tissues
[25].
Expression of CD44 variants in gastric cancer patients
such as CD44v6 and CD44v9 are associated with pro-
gression of gastric cancer [30]. Expression of CD44v6 is
also associated with lymph node metastasis, invasion
and pathological grade of tumor with advanced stages,
patients with CD44v6 positive tumors have a lower sur-
vival rate [34]. Cd44v9 is not expressed on gastric epi-
thelium of H. pylori negative individual, but is present
during H. pylori infection [30]. However, whether CD44
variants can serve as cancer stem cell makers is waiting
for further investigations.Table 3 Putative gastric stem cell and cancer stem cell marke
Name Location Self
CD44 gland base sphe
CD90 n/t sphe
CD133 gland base yes
Musashi-1 antral, isthmus/neck n/t
pSmad2/3L-Thr isthmus region n/t
CD Cluster of differentiation; n/t not tested; pSmad2/3L-Thr Smad2/3 phosphorylateCluster of differentiation 90 (CD90)
CD90 (Thy-1) is a cell surface glycoprotein, molecular
weight at 25–37 kDa. In mice, it is expressed in thymo-
cytes, neuron, T cells; in human, CD90 is expressed in
endothelial, smooth muscle, fibroblasts and a variety of
stem cells; including bone marrow derived mesenchymal
stem cells, hepatic stem/progenitor cells, hematopoietic
stem cells and keratinocytic stem cells [35,36]. CD90
marked cancer stem cells have been identified from
human liver cancer, murine breast tumor and in clinical
gastrointestinal stromal tumor samples [36,37].
CD90 is recently reported to characterize CSC popula-
tion in gastric primary tumors [35]. In isolated human
primary gastric tumor cells, CD90 acts as a surface mar-
ker and can be enriched under non-adherent, serum-free
and sphere-forming conditions. CD90 positive cells
separated from tumor tissue possess a higher ability to
initiate tumor in vivo and reestablish the cellular hier-
archy of tumors from single-cell implantation in nude
mice model, higher proportion of CD90 positive cells
correlate with higher in vivo tumorigenicity in mice [35].
Gene expression analysis indicates stem cell-related
genes are upregulated in sphere-cultured cells, including
CD90, Oct4, Sox2, Notch1 and ALDH1. Oct4 and Sox2
are known embryonic stem cell factors essential for plur-
ipotency and self-renewal of embryonic stem cells.
Notch1 and ALDH1 are markers in both normal and
malignant stem and progenitor cells, but CD133 gene
expression is not increased in these cells [35]. In
addition, blocking ERBB2 pathway can suppress tumori-
genicity, and reduce tumor mass/growth when combined
with traditional chemotherapy [35]. These results sug-
gest CD90 can be a potential cancer stem cell marker
and implicated for monitoring gastric cancers treatment.CD133/Prominin 1 (Prom1)
CD133 is a cell surface membrane protein and a univer-
sal marker for tissue stem/progenitor cells, as well as
CSC; its mouse homologue is Prominin 1. CD133 has
been under intensive investigation as a cancer stem cell
marker in various solid tumors, including gastric, liver,
colorectal, lung, ovarian, prostate, and breast cancers
[33,38].rs
-renewal Xenograft Reference
re formation tumorigenic [32]




d at specific linker threonine.
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apical membranes of Lgr5 positive intestinal stem cells
located at the base of crypts, coexpresses with Lgr5, but
is also expressed on transit-amplifying progenitors. Lin-
age tracing analyses demonstrate that Prom1 marks both
Lgr5 intestinal stem cells and transit-amplifying progeni-
tor cells, generates the entire intestinal epithelium, and
is therefore the small intestinal stem cell marker [39]. In
human stomach, CD133 does not coexpress with stem
cell markers Lgr5 [25]. In gastric cancer patients, CD133
is expressed in more than 50% of the cases, and its ex-
pression appears as an independent prognostic marker
for poor patient prognosis, high CD133 is associated
with poor patient survival rates [40].
Not every gastric epithelial cell line expresses CD133,
probably due to their differentiation stage varies [38]. In
gastric tumor cells lines, CD133(+) cells can form both
CD133(+) and CD133(−) cells; but CD133(−) cells form
only CD133(−) cells, indicating CD133(+) cells retain
the characteristics of self-renewal. When injected into
nude mice, both cells form tumors, but with different
differentiation stages; CD133(−) cell lines form poorly
differentiated tumor while CD133(+) cell lines form well
differentiated tumor [38]. However, using freshly isolated
primary gastric cancer cells, CD133 expression is not
correlated with tumorigenesis both in vitro and in vivo
[33]. Investigation is now focusing on clinically targeting
CD133 and its application in patient outcome prediction
and cancer therapy.
Musashi-1
Musashi-1 (Msi-1), a RNA binding protein associated
with asymmetric divisions in neural progenitor cells, is
identified as a putative stem cell and early linage marker
in mouse intestine [41]. In human stomach, immunos-
taining show that Msi-1 positive cells are located at isth-
mus/neck region of adult antrum, mixed with
proliferating cell nuclear antigen (PCNA) positive cells;
but does not colocalize with PCNA or Ki67, which are
markers for cell proliferation. Msi-1 colocalizes partially
with MUC5AC and MUC6 positive cells [41].
In addition, Musashi-1 is frequently expressed in both
premalignant gastric lesions and invasive gastric cancer
patients, H. pylori infection induces increased Msi-1 ex-
pression in human gastric epithelial cells [42]. Its role in
tumorigenesis has been noticed in intestinal epithelial
cells, yet to be tested in gastric epithelial cells. Double
immunostaining experiment reveals that Musashi-1
coexpresses with stem cell markers Lgr5 cell in both
normal and gastric cancer patient tissues [25], implicat-
ing it has a role in regulating normal epithelial cell dif-
ferentiation, and possibly carcinogenic processes. Future
studies are required to establish its possible role as a
stem cell marker.Smad2/3 phosphorylated at specific linker threonine
(pSmad2/3L-Thr)
Recently, Smad2/3 phosphorylated at specific linker
threonine residues (pSmad2/3L-Thr) has been reported
as a marker for gastric stem cells [43]. pSmad2/3L-Thr
immunostaining positive cells can be specifically
detected in the isthmus region of both gastric corpus
and antral mucosa of C57BL/6 mice. Morphologically,
these cells appear undifferentiated and exhibit a high
nucleus-to-cytoplasm ratio as well as much diffuse chroma-
tin in the nuclei. Double immunostaining staining indicates
that pSmad2/3L-Thr does not colocalize with cell prolifera-
tion marker Ki67, but colocalizes with CK8, indicating
epithelial cell origin. pSmad2/3L-Thr immunostaining-
positive cells colocalize with or near the DCAMKL1
immunostaining-positive cells which is a marker for tuft cells
in gastric corpus mucosa [44], but more works are required
to establish its real identity.
Putative stem cell markers, such as doublecortin and
CaM kinase-like-1 (DCAMKL-1, Dclk1) is previously
identified as intestinal stem cell marker, but later con-
firmed as a marker for gastric tuft cells [44]. Others pu-
tative markers such as identified by FACS side
population with Hoechst dye staining and transcriptional
analyses, including FZD7, HEY1, SMO, and ADAM17
require further investigation to confirm their real iden-
tity [45]. Future investigation to discover reliable stem
cell markers are essential to understand their biology
and pathobiology during H. pylori infection or inflam-
mation induced cancer.
Current understanding on H. pylori interacts with
gastric stem or progenitor cells
The stem cell hypothesis of cancer formation is that
stem or progenitor cells accumulate enough molecular
lesions to evade homeostatic control and result in can-
cer. The damages that originate from genetic and/or epi-
genetic processes are progressively accumulated during
aging and directly contribute to cell transformation [46].
In fact, relatively little information is available about the
effects of H. pylori infection impact on stem cells at
present, although H. pylori has been shown to invade
epithelial cell and their progenitors [47]. During chronic
infection, H. pylori may directly or indirectly interact
with gastric stem/progenitor cells, possibly disrupts their
differentiation and introduces the molecular damage in
these cells. Figure 1 illustrates the possible relationship
of H. pylori infection and the initiation of gastric cancer.
Early studies was performed before the publication of
stem cell markers Lgr5, Villin-promoter; in H. pylori
infected gnotobiotic mouse model of chronic atrophic
gastritis, loss of parietal cells induces amplification of
multi- and oligo-potential gastric stem cells that express
sialylated glycan receptors, which are recognized by
Figure 1 Helicobacter pylori infection, stem cells and gastric cancer. H. pylori infection induces chronic inflammation within local gastric
mucosa; the proinflammatory microenvironment may disrupt stem/progenitor cell proliferation and differentiation. H. pylori- or inflammation-
induced molecular damages in these cells could be carried to the descendants and facilitate tumor initiation. In addition, H. pylori CagA-, cagPAI-
positive strains induce multiple oncogenic signaling and epigenetic alteration in epithelial cells. Persistent activation of these oncogenic
pathways, alterations of epigenetic profile and deregulation of stem cell differentiation provide important molecular mechanisms toward H. pylori-
or inflammation-induced carcinogenesis. (Image is for illustration purpose, does not scale to real size or proportion of cells, and is made by
Microsoft PowerPoint software; CagA: Cytotoxin-associated antigen A; PGN: Peptidoglycan).
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resides within a subset of these progenitor cells [48].
GeneChip-based comparisons of the transcriptome of
mouse gastric progenitor cells (GEP) infected with
H. pylori reveal that H. pylori cancer-associated strain
regulates the expression of GEP-associated signaling and
metabolic pathways; as well as tumor suppressor genes
that are associated with the development of gastric cancer
in humans [49]. These results indicated potential inter-
action of H. pylori with gastric progenitor cells, although
it is not clear if the interaction might lead to tumorigen-
esis, further investigations are required to understand the
consequences and molecular mechanisms.
H. felis infection in mice induced gastric cancers can
originate from bone marrow-derived cells that repopulate
the gastric mucosa [3]. These results have recently been
recapitulated by H. pylori infection in mice model, sug-
gested an important source of gastric cancer [50]. The
infected mice go through gastric chronic inflammation,
intestinal metaplasia and develop stomach cancer. The
fact that cancer formation does not require H. pylori infec-
tion indicate that the general inflammatory status, or
microenvironment, not necessarily bacterial factors or
components, may play a more important role in regulating
stem cell differentiation and the initiation of gastric can-
cer; while H. pylori or H. felis components might promotethis process. These finding are also supported by recent
finding from H. pylori infected gerbil model, in which
H. pylori infection induces remarkable inflammation and
resulted gastric epithelial cell DNA methylation and stom-
ach malignancy; which is caused by inflammation but not
by H. pylori itself [51]. It is clear that epigenetic deregula-
tion is closely related to inflammation, stem cell regulation
and carcinogenesis. Future studies are sorely required to
clarify these links especially during H. pylori infection
model.
H. pylori infection and changes in stem cell
microenvironment or niche
The stem cell niche or microenvironment is composed
of different population of cells, including not only stem
cells, but also differentiated cells, soluble factors, extra-
cellular matrix; all of them are critical for stem cell fate
and differentiation [52]. Important signaling pathways
such as Wnt, Notch, Hedgehog, PI3K, NF-κB, EGF,
TGF-β and STAT3 have been shown to regulate stem
cell renewal and maintenance, their effects overlap in
both normal and cancer stem cells [53], interactions of
stem cell with its surroundings are currently under in-
tensive investigation.
H. pylori infection induces chronic inflammation ac-
companied with increased infiltration of immune cells,
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cosa, and overexpression of inflammatory mediators
such as TNF-α, IL-1β, IL-6, IL-8, COX2, as well as acti-
vation of oncogenic pathways in gastric epithelial cells
[2,9]. These inflammatory mediators and oncogenic
pathways also regulate stem cell differentiation either
directly or indirectly and are frequently deregulated in
tumors [54-56]. Given the fact that gastric stem cells are
such a rare population of cells and can be affected by so
many intrinsic and extrinsic factors, it is obviously very
complicated to identify the specific role of a signal factor
played in regulating their differentiation and migration.
It has been noted that NF-κB, IL-6, VEGF, HIF-1α,
angiogenesis, reactive oxygen species and tissue factors
all involve in the maintenance of stem cell and CSC [53]
and H. pylori infection alters most of their expression;
this provide possibilities that H. pylori will impact on
local microenvironment and affect the stem/progenitor
cell differentiation, as well as causing genetic or epigen-
etic damages in these cell that lead to carcinogenesis.
However, experiments addressing these pathway/media-
tors on the gastric stem/progenitors during infection are
waiting for further investigation.
Chronic inflammation also helps to recruit bone mar-
row derived cells (BMDCs) to the inflammatory site.
BMDCs are a heterogeneous population of cells that in-
clude hematopoietic stem cells and mesenchymal stem
cells (MSCs); they possess high plasticity and can differ-
entiate into cells of diverse lineages, such as stromal
myofibroblasts, epithelial cells, and can give rise to gas-
tric epithelial cells when injected into the adult mouse
stomach or early blastocysts [57]. BMDCs represent an
alternative source of tumor-initiating cells from which a
fraction of tumor cells possesses the capacity for self-re-
newal. MSCs have also been suggested to give rise to
myofibroblasts or cancer-associated fibroblasts that pro-
mote tumor growth [58]. Infection with different strains
of H. pylori is recently shown to induce MSCs migration
through TNF/NF-κB-dependent pathways in epithelial
cells in vitro, therefore provide important link for the
pathogenesis [59].
It is clear that chronic inflammation and proinflamma-
tory status are prerequisite for the initiation of malignant
transformation and tumor progression in inflammatory
diseases such as hepatitis, colitis, pancreatitis and gastric
inflammation [52,60]. In addition, tumor mass progres-
sion involves growth and expansion of tumor cells, stro-
mal cells, blood vessels and infiltrating inflammatory
cells; their interaction propagate tumor progression. The
procarcinogenic inflammatory microenvironment is crit-
ical for this process. Persistent activation of oncogenic
pathways such as MAPK, Wnt, Stat3, HIF, NF-κB and
epigenetic changes are hallmark for the inflammation-
induced cancer.Our understanding has expanded regarding H. pylori
infection and gastric stem cell regulation, due to the re-
cent investigations on these processes within the par-
ticular stem cell microenvironment. However, future
studies are required to define the role of H. pylori or its
components in disrupting stem cell niche, their self-re-
newal, differentiation, and finally tumorigenesis.
Conclusion and future directions
Despite of intensive investigation, the mechanisms of
H. pylori-induced gastric cancer remain poorly under-
stood, the stem cell hypothesis hold the promise to elu-
cidate the origin/initiation of gastric cancer. Study of the
interactions of H. pylori or its virulence factors with
stem/progenitor cells or BMDCs are critical steps lead-
ing toward this purpose. Furthermore, important ques-
tions such as (a) variations in disease susceptibility in
different populations, (b) gastric cancer progression in
relation to H. pylori virulence genes polymorphism, and
(c) the correlation of stem cell with different types of
gastric cancer are all waiting for further clarification.
H. pylori infection triggers inflammation, interactions
of bacteria with host cell in local microenvironment also
affect gastric stem/progenitor cells and their differenti-
ation, this may potentiate oncogenic transformation.
Therefore, focus on H. pylori-induced molecular patho-
genesis and the impact of microenvironment in gastric
stem or progenitor cells will be crucial to identify the
molecular targets in tumor initiation and the origin of
gastric cancer; investigation of which will also provide
insights to uncover the carcinogenic mechanisms and
options for cancer intervention and prevention.
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